|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dialysis |
Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
Address correspondence to: Dr. Cheuk-Chun Szeto, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Phone: +852-2632-3126; Fax: +852-2637-3852; E-mail: ccszeto{at}cuhk.edu.hk
Peritonitis that is caused by Staphylococcus aureus is a serious complication in peritoneal dialysis (PD), but the clinical course of PD-related S. aureus peritonitis remains unclear. All of the S. aureus peritonitis in a dialysis unit from 1994 to 2005 were reviewed. During this period, 2065 episodes of peritonitis were recorded; 245 (11.9%) episodes in 152 patients were caused by S. aureus and 45 (18.4%) episodes were caused by methicillin-resistant S. aureus (MRSA). Patients with a history of recent hospitalization had a higher risk for isolation of MRSA than the others (30.6 versus 14.2%; P = 0.004). The overall primary response rate was 87.8%; the complete cure rate was 74.3%. However, 21 (8.6%) episodes developed relapse and 59 (24.1%) developed repeat S. aureus peritonitis. Episodes that were caused by MRSA had a lower primary response rate (64.4 versus 93.0%; P < 0.001) and complete cure rate (60.0 versus 77.5%; P = 0.023) than the others. Episodes that were treated initially with vancomycin had better primary response rate than those that were treated with cefazolin (98.0 versus 85.2%; P = 0.001), but the complete cure rate was similar. Adjuvant rifampicin treatment was associated with a significantly lower risk for relapse or repeat S. aureus peritonitis than was treatment without rifampicin (21.4 versus 42.8%; P = 0.004). In contrast, initial antibiotic regimen (cefazolin versus vancomycin) and concomitant exit-site infection did not have any effect on the risk for relapse or repeat peritonitis. S. aureus peritonitis is a serious complication of PD. Recent hospitalization is a major risk factor of methicillin resistance in the bacterial isolate. Rifampicin is a valuable adjunct in preventing relapse and repeat S. aureus peritonitis after the index episode.
Related Articles
Clin. J. Am. Soc. Nephrol. 2007 2: 239-244.
J. Am. Soc. Nephrol. 2007 18: 952-959.
This article has been cited by other articles:
![]() |
E. Tacconelli, G. De Angelis, M. A. Cataldo, E. Pozzi, and R. Cauda Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis J. Antimicrob. Chemother., January 1, 2008; 61(1): 26 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Szeto, B. C.-H. Kwan, K.-M. Chow, M.-F. Lau, M.-C. Law, K.-Y. Chung, C.-B. Leung, and P. K.-T. Li Coagulase Negative Staphylococcal Peritonitis in Peritoneal Dialysis Patients: Review of 232 Consecutive Cases Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 91 - 97. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |